Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2019 11:08 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals

ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market...
December 06, 2019 08:42 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals

ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections...
August 09, 2019 08:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of...
July 26, 2019 06:01 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics와 NeuroBo Pharmaceuticals, 퇴행성 질환 치료제 개발 위한 통합 법인 설립 위해 합병 합의

Nasdaq 상장사이자 NeuroBo의 임상단계 파이프라인 발전시킬 바이오 기술기업 탄생 NeuroBo, 신경병적 통증 치료 신약 후보 임상3상 시험 예정 NeuroBo, 최근 Series B 파이낸싱 통해 약 2,424만 달러 조달 Gemphire, 중국 시장 겨냥해 Beijing SL Pharmaceutical Co.와Gemcabene에 대한...
July 26, 2019 06:01 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company

Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain...
July 24, 2019 16:01 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company

Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain...
June 26, 2019 08:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial

LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line...
March 15, 2019 08:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results

LIVONIA, Mich., March 15, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
December 03, 2018 08:00 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update

LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
November 08, 2018 16:01 ET | Source: Gemphire Therapeutics Inc.

Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

LIVONIA, Mich., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...